Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 8.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,752 shares of the life sciences company’s stock after acquiring an additional 218 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Integra LifeSciences Holdings Corporation were worth $150,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of IART. BlackRock Inc. increased its stake in Integra LifeSciences Holdings Corporation by 307,726.8% during the first quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock worth $314,104,000 after acquiring an additional 7,453,142 shares during the last quarter. Vanguard Group Inc. increased its stake in Integra LifeSciences Holdings Corporation by 116.7% during the first quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock worth $238,289,000 after acquiring an additional 3,046,488 shares during the last quarter. Champlain Investment Partners LLC increased its stake in Integra LifeSciences Holdings Corporation by 125.2% during the first quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock worth $187,005,000 after acquiring an additional 2,468,145 shares during the last quarter. FMR LLC increased its stake in Integra LifeSciences Holdings Corporation by 44.1% during the first quarter. FMR LLC now owns 7,615,884 shares of the life sciences company’s stock worth $320,857,000 after acquiring an additional 2,329,710 shares during the last quarter. Finally, Janus Capital Management LLC increased its stake in Integra LifeSciences Holdings Corporation by 311.6% during the first quarter. Janus Capital Management LLC now owns 2,107,875 shares of the life sciences company’s stock worth $88,803,000 after acquiring an additional 1,595,705 shares during the last quarter. 84.90% of the stock is owned by institutional investors.

Several equities research analysts have issued reports on IART shares. Zacks Investment Research cut Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, June 28th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation in a research note on Monday, July 10th. BidaskClub cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Jefferies Group LLC raised their target price on Integra LifeSciences Holdings Corporation from $52.00 to $58.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Finally, ValuEngine cut Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $53.54.

ILLEGAL ACTIVITY WARNING: “Integra LifeSciences Holdings Corporation (IART) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-holdings-raised-by-zurcher-kantonalbank-zurich-cantonalbank/1574827.html.

In related news, Director Donald E. Morel, Jr. purchased 10,000 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was purchased at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the acquisition, the director now owns 29,612 shares in the company, valued at $1,458,391. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Donald E. Morel, Jr. purchased 2,500 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was bought at an average price of $49.29 per share, with a total value of $123,225.00. Following the completion of the acquisition, the director now owns 29,612 shares in the company, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 17,550 shares of company stock valued at $864,842. Insiders own 21.50% of the company’s stock.

Shares of Integra LifeSciences Holdings Corporation (IART) opened at 50.05 on Wednesday. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42. The firm has a market capitalization of $3.91 billion, a PE ratio of 61.04 and a beta of 0.73. The stock has a 50 day moving average price of $50.51 and a 200-day moving average price of $48.58.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 EPS for the quarter, hitting analysts’ consensus estimates of $0.45. The business had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.40 EPS. Equities analysts anticipate that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.